These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28105286)

  • 1. Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases.
    Erra M; Taltavull J; Gréco A; Bernal FJ; Caturla JF; Gràcia J; Domínguez M; Sabaté M; Paris S; Soria S; Hernández B; Armengol C; Cabedo J; Bravo M; Calama E; Miralpeix M; Lehner MD
    ACS Med Chem Lett; 2017 Jan; 8(1):118-123. PubMed ID: 28105286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.
    Hoegenauer K; Soldermann N; Zécri F; Strang RS; Graveleau N; Wolf RM; Cooke NG; Smith AB; Hollingworth GJ; Blanz J; Gutmann S; Rummel G; Littlewood-Evans A; Burkhart C
    ACS Med Chem Lett; 2017 Sep; 8(9):975-980. PubMed ID: 28947947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and optimization of heteroaryl piperazines as potent and selective PI3Kδ inhibitors.
    Zhou H; McGowan MA; Lipford K; Christopher M; Fradera X; Witter D; Lesburg CA; Li C; Methot JL; Lampe J; Achab A; Shaffer L; Goldenblatt P; Shah S; Bass A; Schroeder G; Chen D; Zeng H; Augustin MA; Katz JD
    Bioorg Med Chem Lett; 2020 Jan; 30(1):126715. PubMed ID: 31757666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3Kδ selective inhibitors.
    Bahekar R; Dave B; Soman S; Patel D; Chopade R; Funde R; Kumar J; Sachchidanand S; Giri P; Chatterjee A; Mahapatra J; Vyas P; Ghoshdastidar K; Bandyopadhyay D; Desai RC
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1313-1319. PubMed ID: 30975623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase δ Inhibitor in Experimental Epidermolysis Bullosa Acquisita.
    Koga H; Kasprick A; López R; Aulí M; Pont M; Godessart N; Zillikens D; Bieber K; Ludwig RJ; Balagué C
    Front Immunol; 2018; 9():1558. PubMed ID: 30050528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
    Liu K; Zheng W; Chen Y; Tang M; Li D; Deng D; Yang T; Zhang C; Liu J; Yuan X; Shi M; Li X; Guo Y; Zhou Y; Zhao M; Chen L
    J Med Chem; 2022 Jul; 65(14):9893-9917. PubMed ID: 35831917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From PIM1 to PI3Kδ via GSK3β: Target Hopping through the Kinome.
    Henley ZA; Bax BD; Inglesby LM; Champigny A; Gaines S; Faulder P; Le J; Thomas DA; Washio Y; Baldwin IR
    ACS Med Chem Lett; 2017 Oct; 8(10):1093-1098. PubMed ID: 29057057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.
    Hoegenauer K; Soldermann N; Stauffer F; Furet P; Graveleau N; Smith AB; Hebach C; Hollingworth GJ; Lewis I; Gutmann S; Rummel G; Knapp M; Wolf RM; Blanz J; Feifel R; Burkhart C; Zécri F
    ACS Med Chem Lett; 2016 Aug; 7(8):762-7. PubMed ID: 27563400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization and in vivo evaluation of pyrazolopyridines as a potent and selective PI3Kδ inhibitor.
    Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Moritomo A; Kubo S; Nakamura K; Yamagami K; Hamakawa N; Yokoo K; Fukahori H
    Bioorg Med Chem; 2018 Aug; 26(14):3917-3924. PubMed ID: 29907471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and biological evaluation of novel pyrazolopyridine derivatives as potent and orally available PI3Kδ inhibitors.
    Hamajima T; Takahashi F; Kato K; Mukoyoshi K; Yoshihara K; Yamaki S; Sugano Y; Moritomo A; Yamagami K; Yokoo K; Fukahori H
    Bioorg Med Chem; 2018 May; 26(9):2410-2419. PubMed ID: 29631787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode.
    Down K; Amour A; Anderson NA; Barton N; Campos S; Cannons EP; Clissold C; Convery MA; Coward JJ; Doyle K; Duempelfeld B; Edwards CD; Goldsmith MD; Krause J; Mallett DN; McGonagle GA; Patel VK; Rowedder J; Rowland P; Sharpe A; Sriskantharajah S; Thomas DA; Thomson DW; Uddin S; Hamblin JN; Hessel EM
    J Med Chem; 2021 Sep; 64(18):13780-13792. PubMed ID: 34510892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3Kδ inhibitors.
    Qin LY; Ruan Z; Cherney RJ; Dhar TGM; Neels J; Weigelt CA; Sack JS; Srivastava AS; Cornelius LAM; Tino JA; Stefanski K; Gu X; Xie J; Susulic V; Yang X; Yarde-Chinn M; Skala S; Bosnius R; Goldstein C; Davies P; Ruepp S; Salter-Cid L; Bhide RS; Poss MA
    Bioorg Med Chem Lett; 2017 Feb; 27(4):855-861. PubMed ID: 28108251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and pre-clinical characterization of a selective PI3Kδ inhibitor, LL-00071210 in rheumatoid arthritis.
    Kanoje V; Pandey D; Wagh A; Patra S; Kumar Marisetti A; Reddy M; Samant C; Mahajan N; Gholve M; Sabde S; Trivedi S; Bhankhede T; Patil V; Nigade P; Modi D; Mehta M; Ahirrao P; Tota S; Nanda B; Pawar S; Polawar A; Tamane K; Kuldharan S; Vishwase G; Jana N; Mahangare SJ; Vidhate P; Lagad D; Gundu J; Phukan S; Shukla M; Narasimham L; Nemmani KVS; Bhonde M; Sharma S; Kamboj RK; Palle VP
    Eur J Pharmacol; 2022 Jul; 927():175054. PubMed ID: 35636524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Orally Efficacious Phosphoinositide 3-Kinase δ Inhibitors with Improved Metabolic Stability.
    Patel L; Chandrasekhar J; Evarts J; Forseth K; Haran AC; Ip C; Kashishian A; Kim M; Koditek D; Koppenol S; Lad L; Lepist EI; McGrath ME; Perreault S; Puri KD; Villaseñor AG; Somoza JR; Steiner BH; Therrien J; Treiberg J; Phillips G
    J Med Chem; 2016 Oct; 59(19):9228-9242. PubMed ID: 27660855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
    Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
    Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ).
    Yue EW; Li YL; Douty B; He C; Mei S; Wayland B; Maduskuie T; Falahatpisheh N; Sparks RB; Polam P; Zhu W; Glenn J; Feng H; Zhang K; Li Y; He X; Katiyar K; Covington M; Feldman P; Shin N; Wang KH; Diamond S; Li Y; Koblish HK; Hall L; Scherle P; Yeleswaram S; Xue CB; Metcalf B; Combs AP; Yao W
    ACS Med Chem Lett; 2019 Nov; 10(11):1554-1560. PubMed ID: 31749910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of Selective Benzoxazepin PI3Kδ Inhibitors Through Control of Dihedral Angles.
    Safina BS; Elliott RL; Forrest AK; Heald RA; Murray JM; Nonomiya J; Pang J; Salphati L; Seward EM; Staben ST; Ultsch M; Wei B; Yang W; Sutherlin DP
    ACS Med Chem Lett; 2017 Sep; 8(9):936-940. PubMed ID: 28947940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
    Ma CC; Zhang CM; Tang LQ; Liu ZP
    Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity Target.
    Henley ZA; Amour A; Barton N; Bantscheff M; Bergamini G; Bertrand SM; Convery M; Down K; Dümpelfeld B; Edwards CD; Grandi P; Gore PM; Keeling S; Livia S; Mallett D; Maxwell A; Price M; Rau C; Reinhard FBM; Rowedder J; Rowland P; Taylor JA; Thomas DA; Hessel EM; Hamblin JN
    J Med Chem; 2020 Jan; 63(2):638-655. PubMed ID: 31855425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
    Jia H; Dai G; Su W; Xiao K; Weng J; Zhang Z; Wang Q; Yuan T; Shi F; Zhang Z; Chen W; Sai Y; Wang J; Li X; Cai Y; Yu J; Ren P; Venable J; Rao T; Edwards JP; Bembenek SD
    J Med Chem; 2019 May; 62(10):4936-4948. PubMed ID: 31033293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.